Outcome of patients with multiple myeloma and hypertension treated with angiotensin-I-converting enzyme inhibitors during high-dose chemotherapy

Department of Internal Medicine-Hematooncology, Masaryk University Hospital, Czech Republic.
The Hematology Journal (Impact Factor: 1.86). 02/2005; 5(7):559-64. DOI: 10.1038/sj.thj.6200571
Source: PubMed


In a retrospective study we have sought to determine whether the administration of angiotensin-I-converting enzyme inhibitors (ACEI) influences the outcome of patients with multiple myeloma (MM). Patients with MM who underwent autologous peripheral blood stem cell transplantation (PBSCT) (n=168) were studied. Patients taking ACEI alone or in combination with other antihypertensive agents during the hospital admission for PBSCT were allocated to the ACEI group (n=25; 15%). Patients from the non-ACEI group (n=143; 85%) were taking other or no antihypertensive medication. Patients taking ACEI had worse overall survival (OS) compared to patients not taking ACEI (38.7 versus 73.3 months after diagnosis; P=0.025). Among patients with hypertension, both OS and progression-free survival were significantly shorter in patients taking ACEI. There were no significant differences between the studied groups in standard prognostic parameters for MM (age, albumin, beta 2-microglobulin, IPI and Durie-Salmon stage, LDH, CRP, performance status) or in engraftment. The mortality in our study has been mostly myeloma related. In conclusion, according to our findings, ACEI administered during PBSCT have adverse effect on survival of patients with MM.

Download full-text


Available from: Jiri Minarik, Oct 08, 2014
39 Reads
  • [Show abstract] [Hide abstract]
    ABSTRACT: This review details major new observations in the diagnosis and treatment of leukemias and plasma cell dyscrasias that have been communicated since the last version of this work. This review is not exhaustive and may appear to some to be rather superficial. However, it should serve as an accurate index of current thinking and accomplishments. The review clearly demonstrates a trend away from traditional chemotherapeutic approaches to the leukemias and related diseases in favor of the more rational design of treatments for specific diseases based on laboratory observations. Some refer to the agents that have resulted from such an approach as targeted therapy and suggest that they represent a new era in cancer treatment, although one of the first targeted therapy agents to be conceived, synthesized and tested was 6-mercaptopurine decades ago. Furthermore, there is no cancer therapy more targeted than surgery, which has been practiced longer than any of us has lived. At any rate, whatever slogan may be used to describe current cancer treatment, it is clear that it is based on more preclinical science and more rational design than ever before. This chapter demonstrates that is certainly true for the leukemias and plasma cell dyscrasias. What has not been demonstrated yet is that better rationale has led to better results. That remains to be proven or disproven by continued observation of our treated patients.
    Cancer chemotherapy and biological response modifiers 02/2005; 22(2):343-89. DOI:10.1016/j.uct.2006.05.007
  • [Show abstract] [Hide abstract]
    ABSTRACT: To investigate the association between angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin receptor blockers (ARBs) and disease progression and survival in cancer patients. Using terms for cancer and ACEIs/ARBs, MEDLINE, EMBASE and Web of Science were systematically searched for observational/interventional studies that used clinically relevant outcomes for cancer progression and survival. Ten studies met the inclusion criteria. Two studies showed a significant improvement in overall survival (OS) with ACEI/ARB use among patients with advanced pancreatic (HR 0.52, 95% CI 0.29-0.88) and non-small cell lung cancer (HR 0.56, 95% CI 0.33-0.95). An improvement in progression-free survival (PFS) was also reported for pancreatic cancer patients (HR 0.58, 95% CI 0.34-0.95) and patients with renal cell carcinoma (HR 0.54, p = 0.02). ACEI/ARB use was protective against breast cancer recurrence (HR 0.60, 95% CI 0.37-0.96), colorectal cancer distant metastasis (OR 0.22, 95% CI 0.08-0.65) and prostate specific antigen (PSA) failure in prostate cancer patients (p = 0.034). One study observed a worse OS (HR 2.01, 95% CI 1.00-4.05) and PFS in ACEI users with multiple myeloma (p = 0.085) while another reported an increased risk of breast cancer recurrence (HR = 1.56, 95% CI 1.02-2.39). There is some evidence to suggest that ACEI or ARB use may be associated with improved outcomes in cancer patients. Larger, more robust studies are required to explore this relationship further.
    Cancer Causes and Control 11/2011; 23(2):221-30. DOI:10.1007/s10552-011-9881-x · 2.74 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Angiotensin converting enzyme (ACE) is a circulating enzyme that participates in the body's renin-angiotensin system (RAS) and is localized on the endothelial cell surface in the lung and other vascular beds. It catalyses the conversion of decapeptide angiotensin I to octapeptide angiotensin II. In the present study, we aimed to analyse the possible relationship between the levels of ACE in the context of RAS in multiple myeloma (MM) pathogenesis. The study was conducted on 25 MM patients (13 males, 12 females; median age 66 years, range 47-88) and 20 healthy controls. The clinical features of MM patients including demographics and laboratory findings were summarized. Serum ACE levels were measured by using commercially available kits. The serum ACE levels of MM patients and controls were 32.60±20.26 and 15.35±6.47 respectively. Serum ACE levels were significantly higher in MM patients compared with control groups (p<0.001). Being an important component of RAS, circulating ACE might be associated with clonal proliferation of malignant plasma cells in the bone marrow microenvironment. Identification of the pathobiological activity of the local RAS in MM would enlighten the biologic basis and clinical management of haematologic disorders.
    Journal of Renin-Angiotensin-Aldosterone System 02/2012; 13(2):259-64. DOI:10.1177/1470320312437070 · 2.40 Impact Factor